Aggrilek Infusion

Introduction

Aggrilek is a prescription medication that contains the active ingredient Tirofiban. It is available in the form of an infusion and is used primarily in the treatment of certain heart conditions.

Uses

Aggrilek is prescribed to patients who have undergone certain heart procedures, such as angioplasty or stent placement, to prevent blood clots from forming in the arteries. It is also used in patients with unstable angina or non-ST elevation myocardial infarction (NSTEMI) to reduce the risk of further heart-related events.

Dosage and Administration

Aggrilek should only be administered under the supervision of a healthcare professional. The dosage and duration of treatment may vary depending on the individual patient’s condition and response to therapy. It is typically given intravenously over a specific period of time as directed by the healthcare provider.

Mechanism of Action

Tirofiban, the active ingredient in Aggrilek, belongs to a class of medications known as glycoprotein IIb/IIIa inhibitors. It works by inhibiting the platelets in the blood from sticking together and forming clots. This helps to maintain the patency of the arteries and prevent the occurrence of potentially dangerous blood clots.

Side Effects

Common side effects may include bleeding, such as nosebleeds, bleeding gums, or easy bruising. Serious side effects, although rare, may include severe bleeding, allergic reactions, or a drop in blood platelet count. If any of these side effects occur, seek immediate medical attention.

Drug Interactions

inform your healthcare provider about all medications you are currently taking, including prescription, over-the-counter, and herbal products. Some medications may interact with Aggrilek, potentially increasing the risk of bleeding or reducing its effectiveness. Common examples include other medications that affect platelet function, such as aspirin, clopidogrel, or nonsteroidal anti-inflammatory drugs (NSAIDs).

Precautions

Before starting treatment with Aggrilek, inform your healthcare provider about any known allergies, medical conditions, or medications you are currently taking. This medication should be used with caution in patients with a history of bleeding disorders or recent surgery. Avoid activities that may increase the risk of bleeding, such as excessive physical exertion or the use of certain medications.

Storage

Aggrilek should be stored in accordance with the instructions provided by the healthcare provider or pharmacist. It is typically stored at room temperature, away from direct sunlight, moisture, and heat. Keep the medication out of the reach of children and dispose of any unused medication as directed.

Patient Tips

• Follow the instructions provided by your healthcare provider regarding the administration of Aggrilek.
• Be aware of the signs of bleeding, such as unusual bruising, prolonged bleeding from cuts, or blood in the urine or stool. If you experience any of these symptoms, seek medical attention promptly.
• Inform all healthcare providers, including dentists and surgeons, that you are taking Aggrilek before undergoing any procedures.
• Do not stop taking this medication without first consulting your healthcare provider, as doing so may increase the risk of blood clots.
• If you have any questions or concerns about your treatment with Aggrilek, do not hesitate to speak with your healthcare provider. They are best equipped to provide you with the necessary guidance and support.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Aggrastat 250 mcg/ml Concentrate for Solution for Infusion (Health Professionals SmPC) Available at:
• Tirofiban (Drugs.com) [Accessed 21 Jun. 2024] (online) Available at:
• Enoxaparin Injection (MedlinePlus) [Accessed 1 Jun. 2024] (online) Available at:
• Zi W, Song J, Kong W, Huang J, Guo C, He W, Yu Y, Zhang B, Geng W, Tan X, Tian Y, Liu Z, Cao M, Cheng D, Li B, Huang W, Liu J, Wang P, Yu Z, Liang H, Yang S, Tang M, Liu W, Huang X, Liu S, Tang Y, Wu Y, Yao L, Shi Z, He P, Zhao H, Chen Z, Luo J, Wan Y, Shi Q, Wang M, Yang D, Chen X, Huang F, Mu J, Li H, Li Z, Zheng J, Xie S, Cai T, Peng Y, Xie W, Qiu Z, Liu C, Yue C, Li L, Tian Y, Yang D, Miao J, Yang J, Hu J, Nogueira RG, Wang D, Saver JL, Li F, Yang Q; RESCUE BT2 Investigators. Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion. N Engl J Med. 2023 Jun 1;388(22):2025-2036. doi: 10.1056/NEJMoa2214299. [Accessed 30 Jun. 2024] Available at: